Literature DB >> 28715986

The HIV Care Cascade Among Individuals Under Community Supervision in Baltimore, Maryland.

Nickolas Zaller1, Michael Gordon2, Lauri Bazerman3, Irene Kuo4, Curt Beckwith3.   

Abstract

An estimated one in seven HIV-infected individuals pass through U.S. correctional facilities each year. Transitioning from correctional to community settings may increase HIV treatment interruptions and increase the risk of continued HIV transmission in the community. This study assessed access to HIV providers in the community, antiretroviral treatment, and viral suppression to inform the development of interventions to improve HIV treatment outcomes among individuals involved in community corrections. The sample included 100 individuals under community supervision (probation or parole) in Baltimore, Maryland. While a large proportion of the study sample had undetectable HIV viral loads, 39% did not, and this represents a significant HIV transmission risk. Given the large proportion of individuals involved in the criminal justice system who are under community supervision, community corrections may be an important point of intervention to engage or reengage HIV-positive individuals who are currently out of care.

Entities:  

Keywords:  HIV; community corrections; drug use

Mesh:

Year:  2017        PMID: 28715986     DOI: 10.1177/1078345817709285

Source DB:  PubMed          Journal:  J Correct Health Care        ISSN: 1078-3458


  2 in total

1.  Criminal Justice System Involvement as a Risk Factor for Detectable Plasma HIV Viral Load in People Who Use Illicit Drugs: A Longitudinal Cohort Study.

Authors:  Sarah Ickowicz; N A Mohd Salleh; Nadia Fairbairn; Lindsey Richardson; Will Small; M-J Milloy
Journal:  AIDS Behav       Date:  2019-09

Review 2.  Interventions Designed to Improve HIV Continuum of Care Outcomes for Persons with HIV in Contact with the Carceral System in the USA.

Authors:  Emily F Dauria; Priyanka Kulkarni; Angelo Clemenzi-Allen; Lauren Brinkley-Rubinstein; Curt G Beckwith
Journal:  Curr HIV/AIDS Rep       Date:  2022-06-08       Impact factor: 5.495

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.